http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004098579-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1e3865bbc9b3c9da1b81cc169e193184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c89ce4d9ac03f9acd8ddede1162f94d
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-498
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5355
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5355
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-498
filingDate 2004-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73862374ee3b5380b070e419c1fa3238
publicationDate 2005-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2004098579-A3
titleOfInvention Combination of a glycine/nmda antagonist and a tachykinin nk-1 receptor antagonist for use in the treatment of neurodegeneration
abstract The present invention relates to a pharmaceutical formulation comprising a compound which is active as an antagonist of the strychnine-insensitive glycine modulatory site of the N-methyl-D-asparate (NMDA) receptor in combination with a tachykinin NK-1 receptor antagonist, for use in the treatment of neurodegeneration arising, in particular, from stroke or cerebral ischemia.
priorityDate 2003-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9516679-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9838186-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9609295-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226471508
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419537453
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID4802586
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID750
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCE2AIS8
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419557728
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ868G6
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ9VGE8
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22880
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID406083
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ295T3
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID441071
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCC0HKW2

Total number of triples: 49.